Literature DB >> 9630637

Gene expression and activity of specific opioid-degrading enzymes in different brain regions of the AA and ANA lines of rats.

A Winkler1, M Rottmann, G Heder, P Hyytiä, W E Siems, M F Melzig.   

Abstract

There is increasing evidence that alcoholism runs in families suggesting that genetic factors may play a role. In support of this hypothesis, the alcohol-preferring (AA) and the alcohol-avoiding (ANA) rat lines have been developed through selective outbreeding. Numerous studies indicate that the endogenous opioid system may be involved in controlling ethanol consumption. Changes in opioid peptides and opioid receptors have been described after ethanol intake. But, the influence of ethanol on peptidolytic degradation of opioid peptides has been largely ignored, although the peptidase-mediated metabolism of neuropeptides is known as an important regulatory site of peptidergic transmission. Neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) degrade neuropeptides, including enkephalin and are expressed in the brain. Furthermore, a good correspondence between the regional distribution of NEP and opioid receptors in rat brain has already been reported pointing to a possible role of NEP in regulating opioid peptides. For both enzymes studied, the gene expression pattern was found to be in good agreement with the corresponding enzyme activities in the brain regions investigated, showing the highest levels for both specific mRNAs and enzyme activities in the striatum. Differences in both measured parameters were detected in distinct brain regions of AA and ANA rats. Furthermore, in some brain regions discrepancies between ACE and NEP mRNA levels and the corresponding enzyme activities were observed. For example, in olfactory bulb and striatum such discrepancies were found for both enzymes studied. In tegmentum/colliculi a higher NEP gene expression in AA rats was associated with a higher NEP enzyme activity compared to the amounts found in ANA rats. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630637     DOI: 10.1016/s0925-4439(97)00041-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Acute effects of bradykinin on cerebral microvascular permeability in the anaesthetized rat.

Authors:  M H Sarker; D E Hu; P A Fraser
Journal:  J Physiol       Date:  2000-10-01       Impact factor: 5.182

2.  Acute ethanol administration differentially alters enkephalinase and aminopeptidase N activity and mRNA levels in regions of the nigrostriatal pathway.

Authors:  Marcela Morales-Mulia; Patricia de Gortari; María-Isabel Amaya; Milagros Méndez
Journal:  J Mol Neurosci       Date:  2012-06-12       Impact factor: 3.444

3.  Activity and expression of enkephalinase and aminopeptidase N in regions of the mesocorticolimbic system are selectively modified by acute ethanol administration.

Authors:  Marcela Morales-Mulia; Patricia de Gortari; María-Isabel Amaya; Milagros Méndez
Journal:  J Mol Neurosci       Date:  2011-08-26       Impact factor: 3.444

Review 4.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

5.  New function for an old enzyme: NEP deficient mice develop late-onset obesity.

Authors:  Matthias Becker; Wolf-Eberhard Siems; Reinhart Kluge; Florian Gembardt; Heinz-Peter Schultheiss; Michael Schirner; Thomas Walther
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

6.  Genetic deficiency in neprilysin or its pharmacological inhibition initiate excessive stress-induced alcohol consumption in mice.

Authors:  Björn Maul; Matthias Becker; Florian Gembardt; Axel Becker; Heinz-Peter Schultheiss; Wolf-Eberhard Siems; Thomas Walther
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.